Company news

Rigel Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

July 29, 2024

Rigel Announces Reverse Stock Split

June 24, 2024

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

June 23, 2024

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

June 13, 2024

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 22, 2024

Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

April 29, 2024

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

April 3, 2024

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

March 11, 2024

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 4, 2024

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update

February 26, 2024

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®

February 21, 2024

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

January 3, 2024

Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers

December 7, 2023

Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023

Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition

November 1, 2023

Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update

October 30, 2023

Rigel Announces Presentation at the Upcoming IDWeek 2023

October 10, 2023

Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update

July 31, 2023

Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update

July 24, 2023

Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

June 6, 2023

Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances

June 5, 2023

Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting

May 31, 2023

Rigel to Present at the Jefferies 2023 Global Healthcare Conference

May 30, 2023

Rigel Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023

Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update

April 24, 2023

Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 6, 2023

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update

February 27, 2023

Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances

February 1, 2023

National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

January 17, 2023

Rigel Pharmaceuticals Provides Business Update

January 8, 2023

Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

December 21, 2022

Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

December 14, 2022

Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

November 30, 2022

Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology

November 9, 2022

Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update

November 2, 2022

Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition

November 2, 2022

Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients

October 31, 2022

Rigel Announces Conference Call and Webcast to Report Third Quarter 2022 Financial Results and Business Update

October 26, 2022

Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback

October 9, 2022

Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update

August 1, 2022

Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

August 1, 2022

Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update

July 25, 2022

Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia

June 7, 2022

Rigel Reports First Quarter 2022 Financial Results and Provides Business Update

May 2, 2022

Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update

April 25, 2022

Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology

March 7, 2022

Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

February 28, 2022

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update

February 21, 2022

Rigel Appoints Kamil Ali-Jackson to Board of Directors

December 15, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 15 decks. Every deck is listed under its year.